New data highlight the strength and versatility of Leucid’s proprietary, next-generation technology pCAR has now achieved proof-of-concept across a range of co-stimulatory domains, binders, targets
Financing led by Novartis Venture Fund and joined by new investors 3B Future Health Fund, British Patient Capital, Schroders Capital and Caribou Property alongside founding
Curve’s innovative mammalian cell drug discovery platform to enable identification and optimisation of novel small molecule drug candidates against MSD targets Potentially game-changing platform enables
Edinburgh and Cambridge, UK, 24 January 2022 – Macomics Ltd, an immuno-oncology company with world-leading expertise in macrophage biology, announces today that it has added
The first targeted C3 therapy approved in the EU Approval based on results from head-to-head PEGASUS Phase 3 study where Aspaveli demonstrated superiority to eculizumab
Leucid will work with Lonza on the Cocoon® Platform for Leucid Bio’s Phase I/II clinical studies with its lead candidate, LEU-011, for the treatment of
-Study of lead candidate to provide important information on safety, pharmacokinetics and pharmacodynamics to inform further clinical development in chronic inflammatory diseases–Highlights continued progress advancing
Epidarex-built start-up signs major global development partnership within 18 months of launch. Epidarex portfolio company will receive $24 million in an upfront payment and equity
London, UK – 21 October 2021 – Leucid Bio (“Leucid” or the “Company”), a biotech company pioneering next-generation cell therapies for hard-to-treat cancers, today announces
September 9, 2021 OAKS met the primary endpoint for both monthly and every-other-month treatment with pegcetacoplan, demonstrating a significant reduction in GA lesion growth of